Latest news with #LaurusLabs
Economic Times
4 days ago
- Business
- Economic Times
Laurus Labs shares zoom 19% to hit new all-time high. Is there more heat left?
Laurus Labs stock's recent breakout above the Rs 720–Rs 725 range seems to be a key driver behind its bullish momentum. Laurus Labs surged over 19% in 11 days, hitting a record high of Rs 799.4. Analysts see strong bullish momentum supported by a multi-year breakout, volume patterns, and technical indicators, but advise caution for fresh buyers due to overbought conditions and potential profit-booking zones. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Laurus Labs shares have seen an impressive 19.35% surge in the last 11 days, reaching a new all-time high of Rs 799.4 today on the BSE. This rally has sparked significant investor interest, with technical analysts offering positive insights on the stock's performance and its future stock's recent breakout above the Rs 720–Rs 725 range seems to be a key driver behind its bullish Laurus Labs continues its strong upward trajectory, experts are weighing in on how to approach trading at these elevated levels. While some analysts remain bullish, they also caution investors to be strategic, with key support levels and potential profit-taking zones to Tejas Shah, Senior Vice President of Technical Research at JM Financial Services, Laurus Labs has experienced a multi-year breakout above the Rs 720–Rs 725 levels, sparking a sharp highlighted that this uptrend is supported by increasing volumes during gains and tapering volumes on declines, which is considered a classic sign of healthy stock continues to trade above its 50-day Exponential Moving Average (EMA), reinforcing the positive trend. Mr. Shah further highlighted the emergence of an Ascending Triangle pattern on the weekly chart, which validates the breakout.(Source: JM Financial)The overall chart structure appears strong, and with the relative strength of the stock and favorable sector tailwinds, Laurus Labs is positioned as a strong outperformer in the near to medium expects the stock to potentially move towards Rs 890 and Rs 945 over the next 6 to 12 months, with key support seen in the Rs 720–Rs 725 Gour, Senior Technical Analyst at Swastika Investmart , also weighed in on the stock's strong uptrend, noting that Laurus Labs has made a significant move from the Rs 650–Rs 700 range, showing clear stock is trading above all key moving averages, and the steep upward slope of the 20-SMA and 50-SMA signals strong short-term momentum. Furthermore, the Moving Average Convergence Divergence (MACD) and the Relative Strength Index (RSI) remain in favour of the stock's bullish existing shareholders, Gour advises trailing the stop-loss below the 9-SMA (Rs 755) to protect profits. He also suggests partial profit booking in the Rs 820–Rs 850 zone if momentum starts to slow potential new entrants, however, he cautions against aggressive fresh buying at current levels due to the overbought RSI. Instead, he recommends waiting for a retest of the Rs 755–Rs 770 levels or looking for bullish candle confirmation on lower time-frames before entering the technical outlook for Laurus Labs suggests a strong uptrend, with bullish momentum supported by solid chart structures and favourable sector conditions. While the stock has shown impressive growth recently, analysts recommend a cautious approach for new buyers at current levels.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
4 days ago
- Business
- Time of India
Laurus Labs shares zoom 19% to hit new all-time high. Is there more heat left?
Laurus Labs shares have seen an impressive 19.35% surge in the last 11 days, reaching a new all-time high of Rs 799.4 today on the BSE. This rally has sparked significant investor interest, with technical analysts offering positive insights on the stock's performance and its future potential. The stock's recent breakout above the Rs 720–Rs 725 range seems to be a key driver behind its bullish momentum. As Laurus Labs continues its strong upward trajectory, experts are weighing in on how to approach trading at these elevated levels. While some analysts remain bullish, they also caution investors to be strategic, with key support levels and potential profit-taking zones identified. According to Tejas Shah, Senior Vice President of Technical Research at JM Financial Services, Laurus Labs has experienced a multi-year breakout above the Rs 720–Rs 725 levels, sparking a sharp rally. He highlighted that this uptrend is supported by increasing volumes during gains and tapering volumes on declines, which is considered a classic sign of healthy accumulation. The stock continues to trade above its 50-day Exponential Moving Average (EMA), reinforcing the positive trend. Mr. Shah further highlighted the emergence of an Ascending Triangle pattern on the weekly chart, which validates the breakout. (Source: JM Financial) The overall chart structure appears strong, and with the relative strength of the stock and favorable sector tailwinds, Laurus Labs is positioned as a strong outperformer in the near to medium term. He expects the stock to potentially move towards Rs 890 and Rs 945 over the next 6 to 12 months, with key support seen in the Rs 720–Rs 725 range. Also read: Q1 results season begins: Pace of downgrades may slowdown. Top Nifty, midcap, smallcap stock ideas Pravesh Gour, Senior Technical Analyst at Swastika Investmart , also weighed in on the stock's strong uptrend, noting that Laurus Labs has made a significant move from the Rs 650–Rs 700 range, showing clear momentum. The stock is trading above all key moving averages, and the steep upward slope of the 20-SMA and 50-SMA signals strong short-term momentum. Furthermore, the Moving Average Convergence Divergence (MACD) and the Relative Strength Index (RSI) remain in favour of the stock's bullish momentum. For existing shareholders, Gour advises trailing the stop-loss below the 9-SMA (Rs 755) to protect profits. He also suggests partial profit booking in the Rs 820–Rs 850 zone if momentum starts to slow down. For potential new entrants, however, he cautions against aggressive fresh buying at current levels due to the overbought RSI. Instead, he recommends waiting for a retest of the Rs 755–Rs 770 levels or looking for bullish candle confirmation on lower time-frames before entering the stock. The technical outlook for Laurus Labs suggests a strong uptrend, with bullish momentum supported by solid chart structures and favourable sector conditions. While the stock has shown impressive growth recently, analysts recommend a cautious approach for new buyers at current levels. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Mint
5 days ago
- Business
- Mint
From Laurus Labs, Lupin to Biocon— Pharma stocks rise up to 3% despite Trump's 200% tariff threat
Pharma stocks exhibited remarkable resilience in the morning trade on Wednesday, July 9, despite US President Donald Trump's threat of a very high tariff of up to 200 per cent. Several pharma stocks, including Laurus Labs, Lupin, Biocon, Cipla and Divi's Labs, rose up to 3 per cent in the morning session, pushing their sectoral index, Nifty Pharma, higher by about half a per cent in a weak market. The Nifty Pharma index was up 0.30 per cent at 22,231, around 9:50 AM, with 14 out of the total 20 stocks in the green. Equity benchmark Nifty 50 was 0.13 per cent down at 25,489 at that time. As Mint reported earlier, Trump has warned that pharmaceuticals could face an even steeper tariff, though he suggested the move would not be immediate. 'They're going to be tariffed at a very, very high rate, like 200 per cent,' Trump said, adding that the measure would be announced soon and take effect after at least a year. Steeper tariffs on pharmaceutical imports to the US could be a significant negative for Indian pharma firms, as the US is India's largest overseas market for pharmaceuticals. (This is a developing story. Please check back for fresh updates.)
Business Upturn
02-07-2025
- Business
- Business Upturn
Stocks hitting 52-week highs today, July 2: Divi's Laboratories, Bharti Airtel, UltraTech Cement, Dalmia Bharat and more
By Aman Shukla Published on July 2, 2025, 15:45 IST Despite broader market weakness on July 2, several stocks managed to hit their 52-week highs, signalling strong investor interest. The Sensex slipped 287.60 points to close at 83,409.69, while the Nifty ended 88.40 points lower at 25,453.40. However, the following stocks stood out by touching fresh 52-week highs during the session. Key Stocks That Hit 52-Week Highs Today (July 2) Company Market Price (₹) 52-Week High (₹) Divi's Laboratories 6,859.50 (+0.04%) 6,885.50 Bharti Airtel 2,033.30 (+0.69%) 2,045.80 Laurus Labs 756.75 (+1.43%) 761.75 UltraTech Cement 12,436.00 (+1.85%) 12,527.00 SRF 3,255.60 (+1.74%) 3,281.60 JK Lakshmi Cement 986.00 (+3.56%) 995.00 Federal Bank 217.75 (-0.44%) 220.00 LT Foods 494.75 (+3.95%) 500.00 Dalmia Bharat 2,220.10 (+1.43%) 2,245.00 Ramco Cements 1,088.40 (+1.04%) 1,101.90 Asahi India Glass 830.55 (+3.01%) 842.00 L&T Finance 206.22 (-0.78%) 209.60 AU Small Finance Bank 818.25 (-2.40%) 841.00 KRBL 379.50 (+1.12%) 390.40 Gabriel India 976.20 (+15.84%) 1,011.30 Cholamandalam Financial Holdings 2,148.80 (+1.74%) 2,231.60 South Indian Bank 31.04 (-1.77%) 32.25 Fiem Industries 1,923.30 (-0.77%) 1,999.00 City Union Bank 221.44 (-3.93%) 232.55 Sai Life Sciences 789.10 (+1.19%) 838.50 Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Bharti AirtelDalmia BharatDivi's LaboratoriesStock MarketUltraTech Cement Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
02-07-2025
- Business
- Business Standard
Laurus up for 9th straight day, soars 23% in 1 month. What's driving stock?
Laurus Labs share price: Shares of Laurus Labs continued at their northward movement, hitting a new high of ₹754.15, gaining 1 per cent on the BSE in Wednesday's intra-day trade in otherwise a weak market. The BSE Sensex was down 0.2 per cent at 83,534 at 11:02 AM. The stock of the pharmaceutical company is quoting higher for the ninth straight trading day, surging 17 per cent from level of Rs 645.85 on June 19, 2025. In the past one month, Laurus has outperformed the market and rallied 23 per cent, as compared to 2.7 per cent rise in the BSE Sensex. It has zoomed 93 per cent from its 52-week low of ₹390.30 on August 8, 2024. Laurus Labs FY25 performance, outlook After 3 years of muted earnings, Laurus Labs reported a healthy performance in FY25 with profit more than doubling. Improving asset utilisation driven by project execution in the contract development and manufacturing organisation (CDMO) Operations segment and new launches in the FDF (Finished Dosage Forms), Laurus is expected to report a steady growth in future. Laurus is well-positioned to continue evolving as a diversified CDMO and CMO leader, underpinned by a strong pipeline, enabling technologies, and commercial excellence. The management anticipates operating margins will improve further, supported by continued enhancements in utilization rates and product mix optimisation. Looking ahead, Laurus, in its FY25 annual report, said the company is committed to scaling its global CDMO footprint through continuous capacity expansion and technology investments while advancing into high-value specialty service capabilities such as biologics and gene therapy. Additionally, the company is leveraging automation and AI-driven process optimisation to enhance efficiency and compliance. With a strong foundation and a robust pipeline, the management said the company is well-positioned to capture growth opportunities and reinforce its position as a trusted global CDMO partner. ALSO READ | CARE Ratings revised outlook to stable from negative Revision in the outlook of the long-term rating for bank facilities of Laurus reflects the company's improved performance in FY25, marked by growth in total operating income (TOI), uptick in profitability margins, and strengthening debt coverage indicators. The stable outlook remains supported by anticipated scale-up of the CDMO segment in FY26, which is expected to contribute meaningfully to revenue growth and margin expansion, aided by better capacity utilisation and operational execution. Laurus has 11 manufacturing sites, of which, nine are in Vizag and two in Bangalore. This apart, the company has two Research and Development (R&D) facilities. The company's six manufacturing facilities are approved by the USFDA. Some sites are also approved by other regulatory authorities such as ANVISA Brazil, and WHO Geneva among others. The company has eight manufacturing units for APIs, one for FDF, seven inclusive units for CDMO, and two for bio-ingredients. CareEdge Ratings expects that with improved execution and a higher anticipated contribution from the CDMO segment, the company's margins will expand further by ~150-200 basis points in the coming years. This margin improvement is likely to be supported by enhanced operating leverage, increased focus on value added offerings, and more efficient capacity utilisation within the CDMO business. Going forward, the ratings agency expects that the company's capital structure is expected to strengthen further, supported by improved operational performance and enhanced cash flow generation. Considering cash accruals generated by the company in the recent past and estimated accruals, it is expected that the company would be able to meet its debt obligations comfortably after meeting its capex and increased working capital requirements, CareEdge Ratings said in its rationale dated July 1, 2025.
